NVO and GDRX Related Headlines
Go Back- Oral Wegovy reaches 33% of total prescriptions by May
- Mizuho Reiterates Neutral Rating on GoodRx Holdings Inc. (GDRX)
- BofA Securities Reiterates Underperform Rating on GoodRx Holdings Inc. (GDRX)
- Novo Nordisk offers Ozempic at $499 per month to eligible US cash-paying customers
- GoodRx partners with Novo Nordisk to offer Ozempic, Wegovy for $499 monthly
